Express Pharma

Werum IT Solutions and on/off group enter service partnership

220

Werum customers to benefit from scalable and supplementary services during implementation of their PAS-X MES for DACH region and Europe

Werum IT Solutions has extended its range of services: The on/ off group has been successfully certified as ‘PAS-X Endorsed Service Partner’ for the DACH region and Europe. This qualifies on/ off to support pharma and biotech manufacturers during the implementation phase of Werum’s Manufacturing Execution System (MES) PAS-X at production sites all over Europe. The on/ off group is a leading engineering service provider for process automation and information technologies with headquarters in Germany.

“With the help of the on/ off group, we can support our customers in Europe and especially in the DACH region even more effectively,” said Torsten Isenberg, Senior Director Services, Werum IT Solutions. “As PAS-X Endorsed Service Partner, on/ off takes on typical, easily scalable implementation services such as master data parameterisation, MBR development, validation and on-site go-live support.”

“Through the combination of Werum IT Solutions’ and on/ off’s expertise, our customers will benefit from the long-term, complementary experience of both companies. This partnership is a landmark and future-oriented decision for on/off as well as for Werum. We look forward to an exciting cooperation,” says Björn Müller, MD, on/ off it-solutions.

PAS-X Endorsed Service Partners meet all requirements of Werum IT Solutions’ PAS-X service partner programme. The main objective of the programme is to offer the same quality and competence of services to Werum customers all over the world – through reliable, experienced and certified partners. The service partners need to have comprehensive PAS-X knowledge, participate at PAS-X trainings on a regular basis, possess experience in the regulated industries and use a quality management system. The certification has to be renewed on a regular basis.

- Advertisement -

Comments are closed.